For example, the JMIT study has reported that pemetrexed plus gefitinib achieved a significantly longer PFS [31] and a numerically higher OS rate [32] compared to gefitinib alone as first-line therapy for EGFR-mutated NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.